Skin Disease is More Recalcitrant Than Muscle Disease: Study
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Persistent skin manifestations, especially calcinoses, contribute to morbidity in children with juvenile dermatomyositis (JDM).

A Study was conducted to compare the course of skin and muscle involvement and document frequency of calcinosis in JDM. Prospective cohort study of 184 untreated children was involved with JDM (July 1971-May 2019).

Results:
--Disease activity scores (DAS) were persistently higher for skin vs muscle at all time points; clinical inactivity (DAS less than 2) occurred later for muscle than skin.
--Among DAS-Skin vascular features, eyelid margin capillary dilatation was most frequent (54.3%) and persisted longest. ----Intravenous methylprednisolone reduced DAS-Skin more than oral prednisone at 12 months.
--Overall, 16.8% (n=31) had calcifications, with 4.9% at enrollment. Despite therapy, 25.0% of calcifications recurred and 22.6% failed to resolve; of the latter, 71.4% (n=5) were present at enrollment.
--Children with persistent calcifications had longer duration of untreated disease than those whose calcifications resolved (mean, 12.5 months). Hydroxychloroquine did not improve DAS-skin.

Conclusively, in JDM skin disease presents with greater activity and is more recalcitrant to therapies than muscle disease. Early and aggressive treatment can limit the severity and persistence of calcifications identified later in the disease course.

Source: https://www.jaad.org/article/S0190-9622(20)33223-0/pdf
Like
Comment
Share